The liver represents the hub of our biological world, an extraordinarily valuable organ that is simultaneously exposed to constant toxic and hemodynamic insults. Located at the exact center of metabolism, it receives and processes all substances ingested from the outside through any route of administration. At the same time, it acts as a vital hub responsible for synthesizing and distributing active molecules throughout the entire body. For this reason, maintaining its homeostasis is a fundamental prerequisite for the overall health of all systems. Hepatic functions are multiple, delicate, and in constant dynamic balance with the rest of the body. Dietary imbalance, substrate deficiency, infection, or circulatory disturbance can cause complex functional alterations that, if prolonged over time, develop into genuine structural organ damage, such as hepatic steatosis or steatotic liver disease. The latter, once considered an innocent finding, is now recognized as a silent, chronic condition that can progress to steatohepatitis, fibrosis, and irreversible cirrhosis.
The delicacy of hepatic tissue is accentuated by its extreme susceptibility to drugs, for which it performs primary biotransformation functions that do not always follow protective, goal-oriented criteria, potentially generating intermediate metabolites that are even more toxic than the starting molecule. Many serious adverse reactions at the hepatic level are not dose-dependent but stem from hypersensitivity phenomena that develop over time even at therapeutic doses of common molecules such as nonsteroidal anti-inflammatory drugs (NSAIDs) or antipyretics. When the liver is in a state of overload or intracellular lipid accumulation, a slow trickle of inflammatory cytokines is triggered, fueling low-grade chronic inflammation (Low grade chronic inflammation, LGCI). This silent inflammation, also known as inflammaging, acts as a silent killer: although it does not macroscopically alter classic laboratory markers such as ESR or CRP, it alters membrane permeability, damages hepatocytes, and accelerates tissue fibrosis processes. Early intervention in the organic terrain through a physiological and natural approach not only supports detoxification and drainage functions but also reduces the need for potentially hepatotoxic drugs, protecting the parenchyma during basic treatments.
PRODUCT_ITEM
Dosage and directions for use of MOLTITUDO® LUNAE
To ensure a constant and biologically active supply of the components, in accordance with the body's circadian rhythms and metabolic needs, the following intake schedule is recommended:
· Recommended daily dosage: 2 tablets per day, equivalent to a total of 2 grams of the formulation.
· Timing: The doses must be strictly divided throughout the day, specifically taking 1 tablet during lunch and 1 tablet during dinner.
· Directions for intake: Each tablet should be swallowed whole with a generous sip of natural water, preferably with one of the two main meals.
This precise modulation of the timing of intake allows for the optimization of the kinetics of the phytocomplexes, preventing fluctuations in the concentration of the active principles and maximizing protective efficacy. Do not exceed the indicated daily dose.
The biological rationale and hepato-metabolic support of MOLTITUDO® LUNAE
The choice to administer two tablets of MOLTITUDO® LUNAE per day, divided between lunch and dinner, follows a biochemical logic that combines gastric protection with maximum systemic bioavailability. Taking it with meals is essential because the presence of the food matrix, particularly the lipid portion, facilitates the intestinal absorption of the hydrophobic components of the phytocomplex, minimizing the solubilization and biliary secretion required by the liver. The formula stands out for being 100% vegan, developed in pure tablets, free of sugars and without the use of unnecessary chemical additives, ensuring full compatibility with the most restrictive dietary regimens and excellent long-term tolerability.
The rationale for use is expressed in the powerful multi-level synergy of its three standardized ingredients, which act directly on the cellular pathological mechanisms that link low-grade inflammation to hepatic tissue distress. Bromelain from Pineapple, included at a dosage of 1000 mg per daily dose with an enzymatic activity of 2500 GDU, acts as a systemic cysteine protease. It works by reducing tissue edema, modulating the arachidonic acid cascade, and promoting the drainage of body fluids and toxins accumulated in the extracellular matrix. This process lightens the endogenous toxic load on the natural excretory organs, supporting microcirculation and improving inflammatory states even at the level of the gastrointestinal mucosa.
Boswellia serrata extract, present at 500 mg per daily dose and standardized to 65% boswellic acids (equivalent to 325 mg of active boswellic acids), provides targeted, non-competitive inhibition of the 5-lipoxygenase (5-LOX) enzyme. Since 5-LOX is responsible for the synthesis of leukotrienes, potent pro-inflammatory mediators and neutrophil granulocyte attractants, the action of Boswellia helps extinguish localized inflammatory outbreaks both at the joint and pelvic levels and within the visceral soft tissues. Finally, the formula includes 140 mg of tetrahydrocurcuminoids extracted from Curcuma longa. Tetrahydrocurcuminoids are the active and advanced metabolites of curcumin, characterized by significantly superior chemical stability and intestinal bioavailability compared to the native molecule, overcoming the well-known absorption limitations of traditional turmeric. They exert a dual action: on the one hand, they inhibit the activation of the nuclear factor NF, halting the gene transcription of inflammatory cytokines such as TNF-alpha and interleukin-6, on the other, they stimulate the NRF2 antioxidant pathway. This mechanism increases the synthesis of endogenous protective enzymes such as glutathione peroxidase, essential for neutralizing free radicals and countering oxidative stress and lipid peroxidation that destroy hepatocyte membranes in cases of fatty liver. MOLTITUDO® LUNAE thus serves as a complete physiological support, capable of breaking the link between silent inflammation and fibrotic tissue degeneration.
NOTE: The information provided in the product sheets on this site is for informational and educational purposes only and does not represent medical advice. The published content is not intended to replace the relationship with a doctor or any medical advice, diagnosis, or prescriptions. The information provided describes the ingredients and characteristics of the food supplements, designed to support the body's balance and well-being within a healthy lifestyle. Food supplements are not medicines and must not be used to prevent, diagnose, treat, or alleviate diseases or pathological conditions.
Bibliographic references and clinical sources
· European Association for the Study of the Liver (EASL) (2018). Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. A pivotal study on the evolutionary stages of steatotic liver disease and the inflammatory mechanisms that drive the transition to fibrosis.
· Ammon, H. P. (2006). Boswellic acids in chronic inflammatory diseases. Planta Medica. Research focused on the inhibition of 5-lipoxygenase by boswellic acids and the reduction of pro-inflammatory leukotrienes in visceral tissues.
· Aggarwal, B. B., & Sung, B. (2009). Pharmacological basis of curcumin in chronic diseases. Trends in Pharmacological Sciences. Molecular analysis of the action of curcuminoids on the modulation of NF-$\kappa$B and the suppression of TNF-$\alpha$ and IL-6 cytokines.
· de Souza, G. M., et al. (2019). Is bromelain effective in controlling pain, edema, and trismus? A systematic review and meta-analysis. Phytotherapy Research. Clinical evidence on the systemic efficacy of bromelain in controlling edema, the depolymerization of protein structures, and the drainage of fluids.
· Sengupta, K., et al. (2010). Comparative efficacy and tolerable profile of Boswellia serrata extracts in chronic inflammatory states. International Journal of Medical Sciences. Controlled clinical trial demonstrating the high gastric and hepatic tolerability of Boswellia extracts even in cyclic therapies.
· Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin: a review of cellular and molecular mechanisms. Alternative Medicine Review. Study focused on the ability of turmeric metabolites to activate the NRF2 pathway and reduce cellular oxidative stress.
